Does ROSUVASTATIN Cause Hepatic lesion? 28 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 28 reports of Hepatic lesion have been filed in association with ROSUVASTATIN (Rosuvastatin Calcium). This represents 0.1% of all adverse event reports for ROSUVASTATIN.
28
Reports of Hepatic lesion with ROSUVASTATIN
0.1%
of all ROSUVASTATIN reports
0
Deaths
16
Hospitalizations
How Dangerous Is Hepatic lesion From ROSUVASTATIN?
Of the 28 reports, 16 (57.1%) required hospitalization, and 6 (21.4%) were considered life-threatening.
Is Hepatic lesion Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ROSUVASTATIN. However, 28 reports have been filed with the FAERS database.
What Other Side Effects Does ROSUVASTATIN Cause?
Myalgia (3,958)
Dyspnoea (2,832)
Pain (2,758)
Drug ineffective (2,347)
Fatigue (2,208)
Rhabdomyolysis (2,173)
Arthralgia (1,879)
Asthma (1,843)
Muscle spasms (1,843)
Pain in extremity (1,686)
What Other Drugs Cause Hepatic lesion?
OCTREOTIDE (296)
EVEROLIMUS (171)
RIBOCICLIB (144)
LETROZOLE (139)
CAPECITABINE (124)
ADALIMUMAB (123)
METHOTREXATE (108)
FULVESTRANT (107)
PALBOCICLIB (104)
CYCLOPHOSPHAMIDE (101)
Which ROSUVASTATIN Alternatives Have Lower Hepatic lesion Risk?
ROSUVASTATIN vs ROSUVASTATIN\ROSUVASTATIN
ROSUVASTATIN vs ROTIGOTINE
ROSUVASTATIN vs ROXADUSTAT
ROSUVASTATIN vs ROXICODONE
ROSUVASTATIN vs ROXITHROMYCIN